Aloxi Related Published Studies
Well-designed clinical trials related to Aloxi (Palonosetron)
Anti-emetic effect of ondansetron and palonosetron in thyroidectomy: a
prospective, randomized, double-blind study. [2012]
Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. [2011.04]
Randomized, double-blind, crossover study of palonosetron compared with granisetron for the prevention of chemotherapy-induced nausea and vomiting in a Chinese population. [2011.03]
A Randomized Controlled Trial of Two Different Interventions for the Prevention of Postoperative Nausea and Vomiting: Total Intravenous Anaesthesia using Propofol and Remifentanil versus Prophylactic Palonosetron with Inhalational Anaesthesia using Sevoflurane-Nitrous Oxide. [2011]
Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia. [2010.12.15]
Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer. [2010.11]
Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. [2010.05]
A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy. [2009.11]
Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. [2008.05.01]
Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. [2008.03.07]
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. [2006.09]
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting in elderly patients. [2005.09]
Evaluation of safety and pharmacokinetics of consecutive multiple-day dosing of palonosetron in healthy subjects. [2005.05]
Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. [2005.04]
Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects. [2004.05]
Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. [2004.02]
Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. [2003.12.01]
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. [2003.10]
Well-designed clinical trials possibly related to Aloxi (Palonosetron)
Prevention of delayed nausea: a University of Rochester Cancer Center Community
Clinical Oncology Program study of patients receiving chemotherapy. [2012]
Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. [2011.09]
5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. [2005.10]
Other research related to Aloxi (Palonosetron)
Palonosetron: an evidence-based choice in prevention of nausea and vomiting
induced by moderately emetogenic chemotherapy. [2012]
Palonosetron plus 1-day dexamethasone for the prevention of nausea and vomiting
due to moderately emetogenic chemotherapy: effect of established risk factors on
treatment outcome in a phase III trial. [2012]
A randomized double blind study to evaluate efficacy of palonosetron with
dexamethasone versus palonosetron alone for prevention of postoperative and
postdischarge nausea and vomiting in subjects undergoing laparoscopic surgeries
with high emetogenic risk. [2012]
Palonosetron for prevention of acute and delayed nausea and vomiting in non-small-cell lung carcinoma patients. [2011.12]
Palonosetron Plus 1-Day Dexamethasone for the Prevention of Nausea and Vomiting Due to Moderately Emetogenic Chemotherapy: Effect of Established Risk Factors on Treatment Outcome in a Phase III Trial. [2011.09.22]
Chemotherapy-induced nausea and vomiting and antiemetic prophylaxis with palonosetron versus other 5-HT3 receptor antagonists in patients with cancer treated with low emetogenic chemotherapy in a hospital outpatient setting in the United States. [2011.08]
Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. [2011.08]
Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. [2011.06]
Single-dose palonosetron and dexamethasone in preventing nausea and vomiting induced by moderately emetogenic chemotherapy in breast and colorectal cancer patients. [2011.05]
Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study. [2011.05]
A Randomized Double Blind Study to Evaluate Efficacy of Palonosetron With Dexamethasone Versus Palonosetron Alone for Prevention of Postoperative and Postdischarge Nausea and Vomiting in Subjects Undergoing Laparoscopic Surgeries with High Emetogenic Risk. [2011.04.23]
Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting. [2011.04]
Palonosetron: A novel approach to control postoperative nausea and vomiting in day care surgery. [2011.01]
Palonosetron versus other 5-HT receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies treated with emetogenic chemotherapy in a hospital outpatient setting in the United States. [2011]
Different doses of palonosetron for the prevention of postoperative nausea and vomiting in children undergoing strabismus surgery. [2011]
A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults. [2011]
Palonosetron for prevention of acute and delayed nausea and vomiting in
non-small-cell lung carcinoma patients. [2011]
Randomized, double-blind, crossover study of palonosetron compared with
granisetron for the prevention of chemotherapy-induced nausea and vomiting in a
Chinese population. [2011]
Cost-utility analysis of palonosetron-based therapy in preventing emesis among breast cancer patients. [2010.11]
The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo. [2010.11]
A comparative study between palonosetron and granisetron to prevent postoperative nausea and vomiting after laparoscopic cholecystectomy. [2010.10]
Palonosetron for prevention of acute and delayed nausea and vomiting in non-small-cell lung carcinoma patients. [2010.07.03]
Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer. [2010.07]
Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. [2010.06.25]
Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT(3)R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. [2010.05.22]
Review of palonosetron: emerging data distinguishing it as a novel 5-HT(3) receptor antagonist for chemotherapy-induced nausea and vomiting. [2010.04]
Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting. [2010.02]
Randomized, double-blind, crossover study of palonosetron compared with granisetron for the prevention of chemotherapy-induced nausea and vomiting in a Chinese population. [2010.01.05]
Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT. [2010.01]
Daily palonosetron is superior to ondansetron in the prevention of delayed
chemotherapy-induced nausea and vomiting in patients with acute myelogenous
leukemia. [2010]
Clinical evaluation of two antiemetic combinations palonosetron dexamethasone
versus ondansetron dexamethasone in chemotherapy of head and neck cancer. [2010]
Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist. [2009.12]
Single dose of palonosetron plus dexamethasone to control nausea, vomiting and to warrant an adequate food intake in patients treated with highly emetogenic chemotherapy (HEC). Preliminary results. [2009.12]
Palonosetron: in the prevention of nausea and vomiting. [2009.11.12]
A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy. [2009.11]
Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience. [2009.10]
A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy. [2009.06.26]
Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. [2009.05]
Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response. [2009.04]
Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. [2009.02]
Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy. [2009.02]
The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial. [2009.01]
Palonosetron--a single-dose antiemetic adjunct for hepatic artery radioembolization: a feasibility study. [2009.01]
The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial. [2008.09.30]
Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: Comparison between elderly and non-elderly patient response. [2008.08.23]
Palonosetron Hydrochloride Is an Effective and Safe Option to Prevent Chemotherapy-induced Nausea and Vomiting in Children. [2008.08]
A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo for preventing postoperative nausea and vomiting. [2008.08]
A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo in preventing postoperative nausea and vomiting over a 72-hour period. [2008.08]
Clinical update on palonosetron in the management of chemotherapy-induced nausea and vomiting. [2008.07]
Early Austrian multicenter experience with palonosetron as antiemetic treatment for patients undergoing highly or moderately emetogenic chemotherapy. [2008]
Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. [2007.11]
A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. [2007.11]
Pharmacokinetic evaluation and safety profile of a 15-minute versus 30-second infusion of palonosetron in healthy subjects. [2006.10]
Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist. [2006.10]
Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting. [2006.10]
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. [2006.09]
Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. [2006.09]
New drugs for chemotherapy-induced nausea and vomiting: focus on palonosetron. [2005.06]
Integrating aprepitant and palonosetron into clinical practice: a role for the new antiemetics. [2005.02]
Palonosetron HCl compatibility and stability with doxorubicin HCl and epirubicin HCl during simulated Y-site administration. [2005.02]
Pharmacokinetics, metabolism and excretion of intravenous [l4C]-palonosetron in healthy human volunteers. [2004.11]
Physical and chemical stability of palonosetron HCl in 4 infusion solutions. [2004.10]
Palonosetron: A Unique 5-HT(3) Receptor Antagonist Indicated for the Prevention of Acute and Delayed Chemotherapy-Induced Nausea and Vomiting. [2004.05]
Palonosetron. [2004]
Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis. [2003.12]
Palonosetron (Helsinn). [2002.10]
Other possibly related research studies
Update on anti-emetics for chemotherapy-induced emesis. [2005.08]
[Antiemetic prophylaxis in the chemotherapy of gastrointestinal tumours] [2005.04]
Granisetron: an update on its clinical use in the management of nausea and vomiting. [2004]
The next generation of chemotherapy-induced nausea and vomiting prevention and control: a new 5-HT3 antagonist arrives. [2004.06]
Pharmacological characterization of RS 25259-197, a novel and selective 5-HT3 receptor antagonist, in vivo. [1995.02]
Drug insight: New antiemetics in the management of chemotherapy-induced nausea and vomiting. [2005.04]
Cytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. [2005.10]
Gateways to clinical trials. [2005.07]
5-HT(3)-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatment. [2005]
5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents? [2005.07.01]
Acute emesis: moderately emetogenic chemotherapy. [2005.02]
Same old story? Do we need to modify our supportive care treatment of elderly cancer patients? Focus on antiemetics. [2004]
Gateways to clinical trials. [2004.07]
5-HT3 receptor antagonists for prevention of late acute-onset emesis. [2004.10]
|
